The era of the genome is rapidly expanding to the multiome. This shift is creating opportunities in product portfolio re-positioning and M&A to consolidate technologies that look at DNA, RNA, Protein and Metabolomics from a bulk or single cell based angle. 

Executives across the Healthcare and Life Science industry are rapidly looking for meaningful ways to integrate AI with their strategic objectives. With such a broad set of applications, there is an enormous opportunity in building clear AI strategies that accelerate an organisation at all levels. 

We live in a data rich world, whose content and structure is becoming ever more critical in creating value. There are huge opportunities in bringing data strategy to the forefront of a company's priorities and exploring how it can shape future revenue streams.

Sample preparation technologies are the interface between our physical and digital worlds. As we enhance our understanding of what data signals shape us and our environment, there is an opportunity to re-design sample technologies to maximise its value for a given application. 

As the Life Science and Healthcare industry undergo a major transformation, ensuring this translates to clinical innovation and implementation is imperative. By combining multiomics, AI, data and sample technologies we can create clear strategies to re-imagine the clinical market.